101 related articles for article (PubMed ID: 8369578)
1. Cyclosporin therapy in psoriasis: recommendations for treatment. Italian Multicenter Study Group on Cyclosporin in Psoriasis.
Finzi AF; Ippolito F; Panconesi E; Giannotti B; Rebora A
Dermatology; 1993; 187 Suppl 1():38-40. PubMed ID: 8369578
[No Abstract] [Full Text] [Related]
2. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis.
Dermatology; 1993; 187 Suppl 1():8-18. PubMed ID: 8369579
[TBL] [Abstract][Full Text] [Related]
3. Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
Dermatology; 1993; 187 Suppl 1():30-7. PubMed ID: 8369577
[TBL] [Abstract][Full Text] [Related]
4. Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
Dermatology; 1993; 187 Suppl 1():19-29. PubMed ID: 8369576
[TBL] [Abstract][Full Text] [Related]
5. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
Ho VC; Griffiths CE; Albrecht G; Vanaclocha F; León-Dorantes G; Atakan N; Reitamo S; Ohannesson A; Mørk NJ; Clarke P; Pfister P; Paul C
Br J Dermatol; 1999 Aug; 141(2):283-91. PubMed ID: 10468801
[TBL] [Abstract][Full Text] [Related]
6. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996.
Berth-Jones J; Voorhees JJ
Br J Dermatol; 1996 Nov; 135(5):775-7. PubMed ID: 8977680
[No Abstract] [Full Text] [Related]
7. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis.
Erkko P; Granlund H; Remitz A; Rosen K; Mobacken H; Lindelöf B; Reitamo S
Br J Dermatol; 1998 Dec; 139(6):997-1004. PubMed ID: 9990362
[TBL] [Abstract][Full Text] [Related]
8. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
Ho VC; Griffiths CE; Berth-Jones J; Papp KA; Vanaclocha F; Dauden E; Beard A; Puvanarajan L; Paul C
J Am Acad Dermatol; 2001 Apr; 44(4):643-51. PubMed ID: 11260540
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine in the treatment of psoriasis.
Gulliver WP
Cutis; 2000 Nov; 66(5):365-9. PubMed ID: 11107522
[TBL] [Abstract][Full Text] [Related]
10. Modulation of abnormalities in renal haemodynamics and vasoactive mediators by nifedipine in patients with psoriasis on low-dose cyclosporin.
Edwards BD; Chalmers RJ; O'Driscoll J; Lawson RS; Testa HJ; Ballardie FW
Nephrol Dial Transplant; 1993; 8(10):1071-8. PubMed ID: 8272218
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis: immunopathology and long-term treatment with cyclosporin.
Fry L
J Autoimmun; 1992 Apr; 5 Suppl A():277-83. PubMed ID: 1503622
[TBL] [Abstract][Full Text] [Related]
12. [Cyclosporine and psoriasis].
Mazer JM
Rev Prat; 1991 Oct; 41(22):2183-4. PubMed ID: 1784921
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin in psoriasis: how?
Feldman SR; Garton R
J Eur Acad Dermatol Venereol; 2004 May; 18(3):250-3. PubMed ID: 15096128
[No Abstract] [Full Text] [Related]
14. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
Pedraz J; Daudén E; Delgado-Jiménez Y; García-Río I; García-Díez A
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):702-6. PubMed ID: 16836499
[TBL] [Abstract][Full Text] [Related]
15. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
Maskatia ZK; Koo J
J Drugs Dermatol; 2007 Sep; 6(9):941-4. PubMed ID: 17941368
[TBL] [Abstract][Full Text] [Related]
16. Daily versus intermittent application of high-concentration tacalcitol ointment in combination with low-dose cyclosporin for psoriasis vulgaris.
Abe M; Syuto T; Hasegawa M; Sogabe Y; Yokoyama Y; Ishikawa O
J Dermatol; 2006 Feb; 33(2):108-11. PubMed ID: 16556277
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis.
Edwards BD; Chalmers RJ; O'Driscoll JB; Mitchell DM; Smith RJ; Lawson RS; Testa HJ; Ballardie FW
Clin Nephrol; 1994 Jun; 41(6):350-6. PubMed ID: 8076438
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin in psoriasis: pathophysiology and experimental data.
Mozzanica N; Pigatto PD; Finzi AF
Dermatology; 1993; 187 Suppl 1():3-7. PubMed ID: 8103687
[TBL] [Abstract][Full Text] [Related]
19. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
[TBL] [Abstract][Full Text] [Related]
20. Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis.
Raman GV; Campbell SK; Farrer A; Albano JD; Cook J
J Hypertens Suppl; 1998 Sep; 16(4):S39-41. PubMed ID: 9817191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
